about
Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant usersAbuse liability assessment of tobacco products including potential reduced exposure productsIndicators of drug-seeking aberrant behaviours: the feasibility of use in observational post-marketing cohort studies for risk managementDeterminants of fentanyl and other potent µ opioid agonist misuse in opioid-dependent individuals.Factors associated with the transition from abuse to dependence among substance abusers: implications for a measure of addictive liability.Measures to quantify the abuse of prescription opioids: a review of data sources and metrics.Abuse risks and routes of administration of different prescription opioid compounds and formulations.The use and potential abuse of anticholinergic antiparkinson drugs in Norway: a pharmacoepidemiological study.
P2860
Q28284151-D7A57BFC-C2D3-4A23-B608-F96470E71920Q33559301-97ED19DB-8247-4617-AE9A-D30F353622EEQ34051869-002150E5-DF14-4A4F-A75D-8AF241C84CF5Q34166414-28B4382D-7659-4E94-8EA1-65762AB351FEQ34536352-F21DFC67-F58A-45A5-8131-F1BA08F150CBQ35278475-A1AEA7D3-9955-46FC-A866-23B95A96B2F6Q35541054-E2A01CC2-78B4-40F8-8A69-98B50573A9ABQ37161528-3FBE285C-80DB-4DF0-9FD1-977386194ABA
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Postmarketing surveillance for drug abuse.
@ast
Postmarketing surveillance for drug abuse.
@en
type
label
Postmarketing surveillance for drug abuse.
@ast
Postmarketing surveillance for drug abuse.
@en
prefLabel
Postmarketing surveillance for drug abuse.
@ast
Postmarketing surveillance for drug abuse.
@en
P1476
Postmarketing surveillance for drug abuse.
@en
P2093
Cynthia L Arfken
Theodore J Cicero
P304
P356
10.1016/S0376-8716(03)00102-9
P433
P577
2003-06-01T00:00:00Z